Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction

被引:13
作者
Naumer, Matthias [1 ]
Popa-Wagner, Ruth [1 ]
Kleinschmidt, Juergen A. [1 ]
机构
[1] German Canc Res Ctr, Dept Tumorvirol, D-69120 Heidelberg, Germany
关键词
VIRAL-VECTORS; INTRACELLULAR TRAFFICKING; TYPE-2; THERAPY; IDENTIFICATION; LIBRARIES; TROPISM; CONSEQUENCES; PARTICLES; INFECTION;
D O I
10.1099/vir.0.044735-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Vectors based on adeno-associated virus serotype 2 (AAV2) belong to today's most promising and most frequently used viral vectors in human gene therapy. Like in many other vector systems, the broad but non-specific tropism limits their use for certain cell types or tissues. One approach to screen for transduction-improved vectors is the selection of random peptide libraries displayed directly on the AAV2 capsid. Although the AAV2 library system has been widely applied for the successful selection of improved gene therapy vectors, it remains unknown which steps of the transduction process are most affected and therefore critical for the selection of targeting peptides. Attachment to the cell surface is the first essential step of AAV-mediated gene transduction; however, our experiments challenge the conventional belief that enhanced gene transfer is equivalent to more efficient cell binding of recombinant AAV2 vectors. A comparison of the various steps of gene transfer by vectors carrying a wild-type AAV2 capsid or displaying two exemplary peptide ligands selected from AAV2 random libraries on different human tumour cell lines demonstrated strong alterations in cell binding, cellular uptake, as well as intracellular processing of these vectors. Combined, our results suggest that entry and post-entry events are decisive for the selection of the peptides NDVRSAN and GPOGKNS rather than their cell binding efficiency.
引用
收藏
页码:2131 / 2141
页数:11
相关论文
共 37 条
[1]   Directed evolution of novel adeno-associated viruses for therapeutic gene delivery [J].
Bartel, M. A. ;
Weinstein, J. R. ;
Schaffer, D. V. .
GENE THERAPY, 2012, 19 (06) :694-700
[2]   Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors [J].
Bartlett, JS ;
Wilcher, R ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 2000, 74 (06) :2777-2785
[3]   Gene Therapy Using Adeno-Associated Virus Vectors [J].
Daya, Shyam ;
Berns, Kenneth I. .
CLINICAL MICROBIOLOGY REVIEWS, 2008, 21 (04) :583-593
[4]   Intracellular trafficking of adeno-associated viral vectors [J].
Ding, W ;
Zhang, L ;
Yan, Z ;
Engelhardt, JF .
GENE THERAPY, 2005, 12 (11) :873-880
[5]   Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors [J].
Ferrari, FK ;
Samulski, T ;
Shenk, T ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1996, 70 (05) :3227-3234
[6]   Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis [J].
Fisher, KJ ;
Gao, GP ;
Weitzman, MD ;
DeMatteo, R ;
Burda, JF ;
Wilson, JM .
JOURNAL OF VIROLOGY, 1996, 70 (01) :520-532
[7]   Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 [J].
Grimm, D ;
Kern, A ;
Pawlita, M ;
Ferrari, FK ;
Samulski, RJ ;
Kleinschmidt, JA .
GENE THERAPY, 1999, 6 (07) :1322-1330
[8]  
Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743
[9]  
Heilbronn Regine, 2010, Handb Exp Pharmacol, P143, DOI 10.1007/978-3-642-00477-3_5
[10]   Mutagenesis of Adeno-Associated Virus Type 2 Capsid Protein VP1 Uncovers New Roles for Basic Amino Acids in Trafficking and Cell-Specific Transduction [J].
Johnson, Jarrod S. ;
Li, Chengwen ;
DiPrimio, Nina ;
Weinberg, Marc S. ;
McCown, Thomas J. ;
Samulski, R. Jude .
JOURNAL OF VIROLOGY, 2010, 84 (17) :8888-8902